Q1. After reviewing the FDA's guidance on expedited programs for serious conditions, discuss the pros and cons of priority review and accelerated approval programs.
Q2. What is an FDA advisory committee meeting?
Discuss the importance of regulatory meetings in the development of medicinal products for human use.